Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 6,918 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Stimulation Clear all

Conditions: Major Depressive Disorder
Interventions: exhalatory-gated transcutaneous vagus nerve stimulation (e-RAVANS), Inhalatory-gated transcutaneous vagus nerve stimulation (i-RAVANS); Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 25 Years to 40 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions: Selumetinib, Docetaxel, Placebo, Pegylated G-CSF; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 17
States / cities: Aurora, Colorado • Pembroke Pines, Florida • Atlanta, Georgia + 11 more

Conditions: Sepsis
Interventions: Acupuncture, Sham Acupuncture; Procedure · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Irvine, California

Conditions: Schizophrenia Spectrum Disorders
Interventions: GENUS, Sham Stimulation; Device
Lead sponsor: Massachusetts Institute of Technology; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Chronic Pain, Post Traumatic Stress Disorder (PTSD)
Interventions: Transcranial Direct Current Stimulation (tDCS), Massed-Prolonged Exposure (PE), Sham Transcranial Direct Current Stimulation (tDCS); Device · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 21 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Charleston, South Carolina • Houston, Texas

Conditions: ALS
Interventions: rTMS; Device
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 99 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Epilepsy
Interventions: GTEN 100; Device
Lead sponsor: Electrical Geodesics, Inc.; Industry
Eligibility: 14 Years to 60 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer
Interventions: filgrastim, carmustine, cisplatin, melphalan, vinorelbine tartrate, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atherosclerosis, Coronary
Interventions: Autologous CD34+ Cells, Granulocyte Colony-Stimulating Factor (G-CSF); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Autism Spectrum Disorder
Interventions: Transcranial Magnetic Stimulation (TMS); Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Lymphoma
Interventions: Pegfilgrastim, Loratadine, Placebo, Questionnaires; Drug · Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stroke
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Epilepsy, Essential Tremor, Seizures, Memory Consolidation, Memory Disorders, Memory Replay, Memory Encoding, Cognitive Control, Motor Abilities
Interventions: Cobenfy KarXT pill (50/20 mg), Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Depressive Symptoms, Mild Traumatic Brain Injury, Concussion
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS), Sham rTMS; Device
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Palo Alto, California • Fort Bliss, Texas • Fort Belvoir, Virginia

Conditions: Breast Cancer, Breast Neoplasms
Interventions: FLAC with GM-CSF; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Back Pain
Interventions: TENS, SHAM TENS; Device
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Parkinson Disease
Interventions: Deep Brain Stimulation; Device
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years to 85 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Renal Cancer
Interventions: Dendritic Cell Tumor Fusion Vaccine, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF); Biological · Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: BPSD, Caregiver Distress, Well-being, Mood
Interventions: Personalized Music Listening (PML), Binaural Beat Music (BBM), Spatialized Music (SM); Other
Lead sponsor: Maharishi International University; Other
Eligibility: 55 Years to 95 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Denver, Colorado • Lakewood, Colorado

Conditions: Triple-Negative Breast Cancer
Interventions: Tiragolumab, Atezolizumab, Nab-paclitaxel, Carboplatin, Doxorubicin, Cyclophosphamide, Granulocyte colony-stimulating factor (G-CSF), Granulocyte-macrophage colony-stimulating factor (GM-CSF); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: Birmingham, Alabama • Chicago, Illinois • Charlotte, North Carolina + 2 more

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Myeloproliferative Disorder, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Leukemia
Interventions: Total Body Irradiation, Cyclosporine, Mycophenolate Mofetil, Tocilizumab, Filgrastim; Radiation · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Cervical Spinal Cord Injury
Interventions: Immediate Intervention, Waitlist control; Behavioral
Lead sponsor: Craig Hospital; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Acute Myeloid Leukemia, Myeloid Neoplasm
Interventions: Liposome-encapsulated Daunorubicin-Cytarabine, Cladribine, Cytarabine, Recombinant Granulocyte Colony-Stimulating Factor, Mitoxantrone, Questionnaire Administration, Quality-of-Life Assessment; Drug · Biological · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer
Interventions: sipuleucel-T; Biological
Lead sponsor: Dendreon; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 4
States / cities: Laguna Hills, California • Portland, Oregon • Seattle, Washington

Search by objective public record fields.

Vagus Nerve Stimulation: Integration of Behavior and Cardiac Modulation

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

An Acupuncture Study for People At High Risk for Sepsis

Gamma Light and Sound Stimulation in Schizophrenia

Neuromodulation + Prolonged Exposure Therapy: Evaluation of a Technology-Enhanced, Integrated Treatment for Pain and PTSD

Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS

Transcranial Electrical Neuromodulation for Suppressing Epileptiform Discharges

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer

Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis

Transcranial Magnetic Stimulation (TMS) Study for Adults With Autism Spectrum Disorder (ASD)

Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma

Tactile Learning in Stroke Patients

Human Cognition During Surgery: Stimulation-based and Cholinergic Modulation

rTMS for Military TBI-related Depression

Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast Cancer

TENS for Back Pain Emergency Department

Electrophysiological Recordings of Deep Brain Stimulation in the Basal Ganglia

Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF

Effects of Binaural Beats and Spatialized Music on Behavioural and Psychological Symptoms of Dementia in Assisted Living Facility Residents

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

Spinal Stimulation for Upper Extremity Recovery in the Home

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer